The 2009 ICMlC PA calls for maintaining """"""""development of novel imaging agents and technologies ... in a highly multidisciplinary environment """"""""... with """"""""....""""""""involvement of clinician scientists in all aspects of ICMIC-supported research."""""""" The 2010-2015 UCLA ICMlC goals are consistent with these NCI-ICMIC objectives. The PA Research Projects call for """"""""multi-disciplinary interactions among investigators focused on the ultimate goal of discovering, developing, and translating molecular imaging technologies, imaging sciences, chemistry, radiopharmaceutical chemistry, cell and molecular biology, pathology, pharmacology, computational sciences, and biomedical engineering"""""""". Our proposed projects each focus on a specific disease (Ribas, melanoma;Radu, lymphoma;Wu, soft tissue sarcoma;Herschman, colon cancer). They combine cell biology, specific mouse models for pre-clinical translation, and ongoing or proposed clinical trials of new delivery systems, new imaging probes or multi-modality imaging combinations to stratify patients, predict response to therapy and/or monitor response to alternative therapies. They involve collaborations among basic researchers using animal models, pathologists, radio-chemists, instrumentation engineers, statisticians, clinical oncologists and nuclear medicine experts. The PA proposes that Developmental projects """"""""stimulate interdisciplinary collaborations, while addressing promising emerging research opportunities"""""""". Our proposed projects are relatively high risk proposals that consider new approaches to imaging therapy (Kasahara), switching glucose metabolism in tumors (Chrisofk), monitoring alternative metabolic pathways possibly critical for tumor development (Bensinger) and a new way, not dependent on substrate-enzyme or ligand-receptor interactions, to identify potential imaging probes (Huang). Two 2010 Research projects grew directly from former Developmental projects. We continue and expand the service of our ICMlC Specialized Resources, but add no new Specialized Resources. We continue our Career Development program, funding highly qualified scholars in whom investment to work on molecular imaging problems will, we feel, provide a career-changing experience. The overriding goals of our Research Components, Developmental Funds, Career Development training, Specialized Resources and ICMlC meetings and seminars are (i) to foster incorporation of non-invasive molecular imaging to the best cancer research at UCLA, and (ii) to provide resources to encourage translation of molecular imaging principles and practice to cancer diagnosis, management and therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA086306-14
Application #
8541708
Study Section
Special Emphasis Panel (ZCA1-SRLB-9 (M1))
Program Officer
Menkens, Anne E
Project Start
2000-05-01
Project End
2015-08-31
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
14
Fiscal Year
2013
Total Cost
$1,723,723
Indirect Cost
$583,279
Name
University of California Los Angeles
Department
Pharmacology
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Kim, Woosuk; Le, Thuc M; Wei, Liu et al. (2016) [18F]CFA as a clinically translatable probe for PET imaging of deoxycytidine kinase activity. Proc Natl Acad Sci U S A 113:4027-32
Faltermeier, Claire M; Drake, Justin M; Clark, Peter M et al. (2016) Functional screen identifies kinases driving prostate cancer visceral and bone metastasis. Proc Natl Acad Sci U S A 113:E172-81
Kirkby, Nicholas S; Chan, Melissa V; Zaiss, Anne K et al. (2016) Systematic study of constitutive cyclooxygenase-2 expression: Role of NF-κB and NFAT transcriptional pathways. Proc Natl Acad Sci U S A 113:434-9
Tavaré, Richard; Escuin-Ordinas, Helena; Mok, Stephen et al. (2016) An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy. Cancer Res 76:73-82
Atefi, Mohammad; Titz, Bjoern; Tsoi, Jennifer et al. (2016) CRAF R391W is a melanoma driver oncogene. Sci Rep 6:27454
Clark, Peter M; Mai, Wilson X; Cloughesy, Timothy F et al. (2016) Emerging Approaches for Targeting Metabolic Vulnerabilities in Malignant Glioma. Curr Neurol Neurosci Rep 16:17
Zaiss, Anne K; Foley, Erin M; Lawrence, Roger et al. (2016) Hepatocyte Heparan Sulfate Is Required for Adeno-Associated Virus 2 but Dispensable for Adenovirus 5 Liver Transduction In Vivo. J Virol 90:412-20
Barrio, Martin; Czernin, Johannes; Yeh, Michael W et al. (2016) The incidence of thyroid cancer in focal hypermetabolic thyroid lesions: an 18F-FDG PET/CT study in more than 6000 patients. Nucl Med Commun 37:1290-1296
Mok, Stephen; Tsoi, Jennifer; Koya, Richard C et al. (2015) Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition. BMC Cancer 15:356
Evdokimov, Nikolai M; Clark, Peter M; Flores, Graciela et al. (2015) Development of 2-Deoxy-2-[(18)F]fluororibose for Positron Emission Tomography Imaging Liver Function in Vivo. J Med Chem 58:5538-47

Showing the most recent 10 out of 216 publications